Drug Trial Radar · NCT07560033
A Comparative Pharmacokinetic Study of CM326 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
192
Planned (sponsor's estimate)
Start
Apr 20, 2026
Primary completion
Oct 1, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, open-label, parallel-controlled study to compare the PK, safety, and immunogenicity of CM326 administered via different delivery devices in healthy subjects.
Conditions
- Healthy Subjects
Interventions
CM326(formulation 1)Drug
subcutaneous injection
CM326(formulation 2)Drug
subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum concentration (Cmax)Time frame: Pre-dose at day 1 to Day 113
- Area under the concentration-time curve from zero to infinity (AUCinf)Time frame: Pre-dose at day 1 to Day 113
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.